Evista (chemical name: raloxifene) is a SERM approved by the U.S. Food and Drug Administration (FDA) to: 1  reduce the risk of hormone-receptor-positive breast cancer in postmenopausal women who haven't been diagnosed but are at higher-than-average risk for disease.
Types of paper ICT Express publishes original research papers in English in the fields of ICT convergence, platform technologies, communication networks, and device technologies. ICT Express accepts short-length (up to 4 pages in double columns and additional 2 pages will be allowed with over page charge (100USD/1page)) high-quality, original articles in Latex or Word format. Sample manuscript can be downloaded here.
Published in the US more than 30 days after publication abroad, without compliance with US formalities, and not in the public domain in its home country as of 1 January 1996 (but see special cases) 95 years after publication date.